Key Takeaways
- • Jeito Capital completed final closing of Jeito II at $1.2 billion (€1 billion), exceeding its target and establishing a new benchmark for European Biopharma private equity fundraising.
- • The fund deployment has tripled Jeito's total assets under management to €1.6 billion since Jeito I closed in 2021 at $630 million, positioning the firm as a leading independent European Biopharma investor.
- • Jeito II's capital increases average investment capacity to €150 million per portfolio company, enabling deeper support through successive value inflection points in clinical-stage development.
- • The fund is actively deployed across obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology, and cardio-metabolic diseases—therapeutic areas with strong commercial demand driven by the pharmaceutical patent cliff.
- • Jeito's strategy directly addresses industry consolidation dynamics: over 70% of innovative new drugs now originate from smaller Biopharma companies as major pharmaceutical firms face potential $400 billion revenue decline by 2033 from patent expirations.
Summary
Jeito Capital announced the final closing of Jeito II at $1.2 billion (€1 billion), exceeding its fundraising target and marking a significant milestone for European Biopharma private equity. The oversubscribed close positions Jeito as a leading fully independent European Biopharma investor and reflects institutional confidence in the firm's clinical-stage investment thesis and operating model.
The successful fundraise has tripled Jeito's assets under management to €1.6 billion, building on the 2021 closing of Jeito I at $630 million (€534 million). This capital increase enables the firm to increase average investment sizes to €150 million per portfolio company, strengthening its ability to support clinical-stage biotech companies through successive development milestones and value creation inflection points.
Jeito II has already begun active capital deployment across high-demand therapeutic areas including obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology, and cardio-metabolic diseases. The fund's strategy targets high-potential clinical Biopharma companies developing breakthrough therapies for patients with severe, unmet medical needs. This focus directly addresses structural shifts reshaping the pharmaceutical industry: the impending patent cliff threatens a potential $400 billion decline in pharmaceutical revenues by 2033 as exclusivity expires on blockbuster drugs representing over 50% of certain companies' annual sales.
This market dynamic is driving strategic consolidation and increased external investment in innovation. According to the firm's analysis, more than 70% of innovative new drugs now originate from smaller Biopharma companies, reinforcing the strategic importance of M&A activity and the investment opportunities available to specialized Biopharma funds. Jeito's patient-driven investment approach and commitment to progressive capital deployment position it to capitalize on this structural trend while addressing the industry's innovation imperative.
The successful fundraise has tripled Jeito's assets under management to €1.6 billion, building on the 2021 closing of Jeito I at $630 million (€534 million). This capital increase enables the firm to increase average investment sizes to €150 million per portfolio company, strengthening its ability to support clinical-stage biotech companies through successive development milestones and value creation inflection points.
Jeito II has already begun active capital deployment across high-demand therapeutic areas including obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology, and cardio-metabolic diseases. The fund's strategy targets high-potential clinical Biopharma companies developing breakthrough therapies for patients with severe, unmet medical needs. This focus directly addresses structural shifts reshaping the pharmaceutical industry: the impending patent cliff threatens a potential $400 billion decline in pharmaceutical revenues by 2033 as exclusivity expires on blockbuster drugs representing over 50% of certain companies' annual sales.
This market dynamic is driving strategic consolidation and increased external investment in innovation. According to the firm's analysis, more than 70% of innovative new drugs now originate from smaller Biopharma companies, reinforcing the strategic importance of M&A activity and the investment opportunities available to specialized Biopharma funds. Jeito's patient-driven investment approach and commitment to progressive capital deployment position it to capitalize on this structural trend while addressing the industry's innovation imperative.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.